Available Brands
Did you find this information helpful?
Author Details
Written By
Vishishta
M.Sc Microbiology

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 15 Oct 2026 | 05:28 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
BARICITINIB
Last updated on 15 Oct 2026 | 05:28 AM (IST)
BARICITINIB
Molecule Overview
Baricitinib is an oral targeted medicine that calms an overactive immune system by blocking specific signalling pathways inside immune cells. It belongs to a class of medicines called JAK (Janus kinase) inhibitors, used for rheumatoid arthritis, severe alopecia areata (an autoimmune form of hair loss), and certain hospitalised COVID-19 patients. It is a prescription-only medicine that carries a boxed warning.
Medical Classification
Therapeutic Class: Targeted immunomodulator for autoimmune/inflammatory conditions.
Pharmacological Class: Janus kinase (JAK) inhibitor, targeting JAK1 and JAK2.
Drug Family: Small-molecule JAK inhibitors.
ATC Classification: L04AA37 (Baricitinib).
Conditions Treated
Approved: Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more TNF blockers; severe alopecia areata in adults; and treatment of COVID-19 in certain hospitalised adults requiring supplemental oxygen or ventilatory support.
Commonly used for: Adults with rheumatoid arthritis not adequately controlled by standard therapy, and adults with severe alopecia areata (defined as 50% or greater scalp hair loss).
Off-label use (only under medical guidance): Being studied in other autoimmune/inflammatory conditions in clinical trials; use outside approved indications is a specialist decision.
Available Strengths & Dosage Forms
● Oral tablets: 1 mg, 2 mg, and 4 mg.
How the Molecule Works
Baricitinib blocks enzymes called Janus kinase 1 and 2 (JAK1/JAK2), which immune cells use to relay signals from inflammatory messengers (cytokines) that drive conditions like rheumatoid arthritis and alopecia areata. By blocking this signalling pathway, baricitinib reduces the inflammatory activity that damages joints or attacks hair follicles, depending on the condition being treated.
Dosage & Administration
Standard dose (rheumatoid arthritis): 2 mg taken orally once daily, with or without food.
Condition-wise dose (alopecia areata): 2 mg once daily for most patients; may be increased to 4 mg once daily if response is inadequate, particularly for patients with nearly complete or complete scalp hair loss — once an adequate response is achieved on 4 mg, the dose may be decreased back to 2 mg.
Route: Oral, once daily, with or without food.
Missed dose: Take as soon as remembered on the same day; don't double up.
Overdose: May increase the risk of infection or other known side effects; requires medical attention.
Side Effects
Common: Upper respiratory tract infections, nausea, headache, and elevated cholesterol (LDL) levels.
Serious: Serious infections (including tuberculosis reactivation), decreases in blood counts (neutropenia, lymphopenia), and elevated liver enzymes.
Emergency symptoms: Signs of serious infection (fever, chills, persistent cough), chest pain, sudden weakness or slurred speech (possible stroke), leg swelling or pain (possible blood clot), or unusual bleeding or bruising.
Recovery advice: Because baricitinib affects the immune system, prompt reporting of any new infection symptoms is important; scheduled blood tests allow early detection of blood count, cholesterol, or liver enzyme changes.
Warnings & Precautions
Pregnancy: Not recommended; may cause fetal harm.
Breastfeeding: Not recommended during treatment.
Liver disease: Used with caution; liver enzymes are monitored during treatment; not recommended in severe hepatic impairment.
Kidney disease: Dose reduction is required in moderate to severe kidney impairment.
Elderly: Used with particular caution in patients 50 and older with cardiovascular risk factors, given the boxed warning.
Children: Not approved for use in children.
Drug Interactions
● Other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine, cyclosporine): not recommended in combination, due to increased risk of excessive immunosuppression.
● OAT3 inhibitors (e.g., probenecid): can increase baricitinib levels, requiring dose adjustment.
● Live vaccines: should be avoided during treatment; vaccinations should be brought up to date before starting.
● Strong immunosuppressants in combination generally avoided, given the cumulative infection risk.
Monitoring Requirements
● Complete blood counts (neutrophils, lymphocytes) before and during treatment.
● Liver function tests periodically.
● Lipid profile, given associated cholesterol increases.
● Screening for tuberculosis and viral hepatitis before starting; ongoing monitoring for infection signs throughout treatment.
Alternative Molecules
Upadacitinib, Tofacitinib (other JAK inhibitors); Adalimumab, Etanercept (TNF blockers, different mechanism, often used before JAK inhibitors in rheumatoid arthritis).
Combination Therapies
Often used alongside methotrexate in rheumatoid arthritis, though it can also be used as monotherapy; not combined with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants like azathioprine or cyclosporine.
● Rheumatoid Arthritis Medicines
● Alopecia Areata Treatments
● JAK Inhibitors
FAQs
Q1.
It's used to treat moderately to severely active rheumatoid arthritis not adequately controlled by TNF blockers, severe alopecia areata, and certain hospitalised COVID-19 patients.
Q2.
JAK inhibitors as a class have been linked to increased risks of serious infection, certain cancers, major cardiovascular events, and blood clots, particularly in older patients with cardiovascular risk factors.
Q3.
Both conditions commonly start at 2 mg once daily, but for alopecia areata, the dose may be increased to 4 mg for patients with more extensive hair loss if the initial response is inadequate.
Q4.
No, it's not recommended to combine baricitinib with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants like azathioprine or cyclosporine, due to increased infection risk.
Q5.
Regular complete blood counts, liver function tests, and lipid profile checks are recommended throughout treatment.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






